8-K: SHF Holdings Boosts Capital, Clears Debt with $28.8M Securities Deal

Sentiment:

Current Report 3 October 2025 4:58 PM

SHF Holdings, Inc. announced a series of strategic financial transactions, including a $28.8 million securities purchase agreement and debt cancellations, aimed at strengthening its balance sheet and regaining Nasdaq compliance.

Delay expectedThe ongoing government shutdown, and its potential effects, may affect the length of time before the registration statement on Form S-1 for resale of securities is declared effective by the SEC.

Capital raiseThe Company entered into a Securities Purchase Agreement to issue 31,052 shares of Series B Convertible Preferred Stock and warrants for 1,999,544 shares of Class A Common Stock, raising approximately $28.8 million in aggregate purchase price, with net cash proceeds of approximately $6.1 million.The purchase price was satisfied through a combination of cash, cancellation of outstanding indebtedness/securities, cancellation of amounts owed, and transfer of assets.An amendment to the Common Stock Purchase Agreement with CREO Investments LLC stipulates that 25% of net cash proceeds from future Class A Common Stock sales will be applied towards the redemption of Series B Convertible Preferred Stock.

Better than expectedThe Company successfully raised approximately $6.1 million in net cash, improving its financial position.It significantly reduced its debt by cancelling approximately $10.7 million in secured debt and $687,500 in convertible notes.The Company believes these actions have brought it back into compliance with Nasdaq's minimum stockholders' equity requirement, addressing a previous delisting notice.

Summary

SHF Holdings, Inc. (SHFS) entered into a Securities Purchase Agreement to issue 31,052 shares of Series B Convertible Preferred Stock and warrants to acquire 1,999,544 shares of Class A Common Stock.
The aggregate purchase price for these securities was approximately $28.8 million, resulting in approximately $6.1 million in net cash proceeds for the Company.
A Debt Cancellation Agreement with Partner Colorado Credit Union (PCCU) extinguished an outstanding principal amount of approximately $10.7 million, in exchange for 13,436 shares of Series B Preferred Stock and a warrant for 865,200 shares of Class A Common Stock.
The Company also entered into Exchange and Cancellation Agreements with Verdun Investments LLC, Vellar Opportunity Fund SPV LLC – Series 1, and Midtown East Management NL, LLC, terminating a Forward Purchase Agreement from June 16, 2022, in exchange for Series B Preferred Stock and Warrants.
Convertible Promissory Notes totaling $687,500 were exchanged for 825 shares of Series B Preferred Stock and warrants for 53,127 shares of Class A Common Stock, eliminating all outstanding convertible debt.
An amendment to the Common Stock Purchase Agreement with CREO Investments LLC mandates that 25% of net cash proceeds from future Class A Common Stock sales will be used to redeem Series B Convertible Preferred Stock.
The Company believes these transactions have restored its compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million, following a delisting notice on April 7, 2025.

Sentiment

Score: 8

Explanation: The Company successfully executed a multi-faceted financing and debt restructuring, significantly improving its balance sheet, raising capital, and addressing a critical Nasdaq compliance issue. While dilution and future redemption obligations exist, the immediate financial and regulatory improvements are substantial positives.

Positives

Successfully raised approximately $6.1 million in net cash proceeds, strengthening liquidity.
Eliminated approximately $10.7 million in secured debt through a debt-for-equity exchange, reducing financial leverage.
Cancelled all outstanding convertible debt totaling $687,500, simplifying the capital structure.
Believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement, mitigating delisting risk.
Secured registration rights for investors, facilitating future liquidity for the newly issued securities.

Negatives

Issuance of significant Series B Convertible Preferred Stock and warrants could lead to substantial dilution for existing common stockholders upon conversion/exercise.
The Series B Preferred Stock has a liquidation preference of 125% of its conversion amount, ranking senior to common stock.
The Company is obligated to apply 25% of net cash proceeds from future common stock sales towards redeeming Series B Preferred Stock, potentially limiting capital for other corporate purposes.
Certain members of management and the board participated in the securities purchase, with underlying common stock issuance subject to stockholder approval, which could raise corporate governance concerns if not handled transparently.

Risks

Dilution Risk: Significant issuance of Series B Convertible Preferred Stock and warrants could substantially dilute the ownership interests of existing common stockholders upon conversion or exercise.
Regulatory Compliance Risk: The Company awaits Nasdaq's confirmation of compliance with listing rules; failure to maintain compliance could lead to delisting.
Market Volatility: Forward-looking statements acknowledge the impact of recent volatility in capital markets, which may adversely affect the price of the Company's securities.
Government Shutdown Impact: A potential government shutdown may affect the length of time before the registration statement for resale of securities is declared effective by the SEC.
Stockholder Approval Risk: Issuance of underlying Class A Common Stock to management and board members is subject to stockholder approval under Nasdaq Listing Rule 5635(c); failure to obtain this could create issues.
Cannabis Industry Trends: The Company's future performance is subject to trends in the cannabis industry, including proposed changes in U.S. and state laws, rules, regulations, and guidance.
Liquidation Preference: Series B Preferred Stock holders have a liquidation preference of 125% of their conversion amount, which could impact common stockholders in a liquidation event.
Covenant Breaches: Various 'Triggering Events' in the Certificate of Designations, such as failure to file/maintain registration, failure to pay dividends, or default on $500,000+ indebtedness, could lead to adverse consequences for the Company.
Future Capital Needs: The Company's ability to obtain requisite stockholder approvals and its growth prospects are subject to future capital needs and market conditions.

Future Outlook

The Company anticipates that its stockholders' equity will exceed $2.5 million at December 31, 2025, and expects to regain Nasdaq compliance. It plans to file a registration statement on Form S-1 for resale of underlying securities by October 29, 2025, and will use commercially reasonable efforts to ensure its effectiveness. The Company's future performance is tied to trends in the cannabis industry, potential changes in U.S. and state laws, and its ability to produce competitive products, while acknowledging capital market volatility and potential impacts from government shutdowns.

Management Comments

We believe these transactions have restored our compliance with Nasdaq's minimum stockholders' equity requirement.
We anticipate that the information contained in our Quarterly Report on Form 10-Q for the period ended September 30, 2025 will reflect this.
We also believe that our stockholders' equity will continue to exceed $2.5 million at December 31, 2025.

Industry Context

The filing mentions the Company's future performance is subject to trends in the cannabis industry, including proposed changes in U.S. and state laws, rules, regulations, and guidance. This indicates the Company operates within or is significantly exposed to the cannabis sector, where regulatory shifts can have a substantial impact on business operations and growth prospects. The strategic financing and debt restructuring could position the Company to better navigate these industry-specific challenges and capitalize on future opportunities, assuming favorable regulatory developments.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
New Preferred Stock Designation	Filed a Certificate of Designation for Series B Convertible Preferred Stock, outlining its preferences, rights, and limitations, including dividend rights, conversion terms, liquidation preferences, and voting restrictions.	2025-09-30	Introduces a new class of preferred stock with specific rights that rank senior to common stock in liquidation and potentially in dividends, impacting common shareholder value and corporate flexibility. Includes anti-dilution provisions and company redemption rights.
Stockholder Approval Requirement	Issuance of Class A Common Stock underlying Series B Preferred Stock and Warrants to certain management and board members is subject to stockholder approval under Nasdaq Listing Rule 5635(c).	2025-09-30	Ensures compliance with Nasdaq rules for related-party equity issuances, requiring shareholder endorsement for these specific allocations.
Authorized Shares Increase Obligation	Company is obligated to take all necessary action to increase authorized common stock to meet the Required Reserve Amount for conversions/exercises, including calling special stockholder meetings if needed.	2025-09-30	Ensures sufficient common stock is available to satisfy conversion and exercise rights, preventing potential breaches of agreements and maintaining investor confidence, but requires ongoing corporate action and potential shareholder votes.
Covenants on Indebtedness and Liens	Restrictions on incurring new indebtedness (other than Permitted Indebtedness) and allowing liens (other than Permitted Liens).	2025-09-30	Limits the Company's financial flexibility but protects preferred shareholders by restricting further encumbrances on assets and excessive debt accumulation.
Restrictions on Restricted Payments and Investments	Prohibits redemption, repurchase, or cash dividends on other capital stock (except as required by Series B terms) and certain investments if a Triggering Event has occurred or is continuing.	2025-09-30	Prioritizes Series B Preferred Stock obligations and restricts capital distributions to common shareholders under adverse conditions, enhancing the security for preferred holders.
Restrictions on Transfer of Assets and Business Nature	Limits sales, leases, or other dispositions of material assets outside the ordinary course of business and prohibits engaging in materially different lines of business or modifying corporate structure/purpose.	2025-09-30	Maintains the Company's core business and asset base, providing stability for investors but potentially limiting strategic flexibility for major divestitures or business pivots.

Related Party Transactions

Certain members of the Company's management and board participated as Buyers in the Securities Purchase Agreement. The issuance of Class A Common Stock underlying the Series B Preferred Stock and Warrants to these individuals is subject to stockholder approval under Nasdaq Listing Rule 5635(c).
The amendment to the Common Stock Purchase Agreement was with CREO Investments LLC, which is also a Buyer in the Securities Purchase Agreement and is mentioned as the 'lead Buyer' in the Registration Rights Agreement.

Stakeholder Impact

Shareholders (Common Stock): Potential for significant dilution due to the issuance of convertible preferred stock and warrants. Liquidation preference of Series B Preferred Stock ranks senior to common stock. Future cash proceeds from CSPA sales will be partially diverted to redeem Series B Preferred Stock, potentially reducing funds available for common shareholders or other corporate growth initiatives.
Preferred Shareholders (Series B): Benefit from debt reduction, capital infusion, and specific protective provisions in the Certificate of Designations, including liquidation preference, anti-dilution rights, and company redemption options. Their investment is secured by various covenants.
Creditors: The cancellation of approximately $10.7 million in secured debt improves the Company's overall debt profile and financial health, potentially making the Company a more attractive borrower in the future.
Management/Board: Certain members participated in the securities purchase, indicating their continued investment and alignment with the Company's future, though their specific equity issuances require stockholder approval.
Nasdaq: The transactions are expected to bring the Company back into compliance with listing requirements, maintaining its public trading status.

Next Steps

File a registration statement on Form S-1 with the SEC as soon as practicable, but no later than October 29, 2025, to register the Class A Common Stock underlying the Series B Preferred Stock and Warrants for resale by the Buyers.
Use good faith commercially reasonable efforts to cause the registration statement to be declared effective by the SEC as soon as practicable after filing.
Obtain stockholder approval under Nasdaq Listing Rule 5635(c) for the issuance of Class A Common Stock underlying Series B Preferred Stock and Warrants to certain members of management and the board.
The Company will hold a meeting of its stockholders for the approval of an increase in the number of authorized shares of Common Stock, if necessary, to meet the Required Reserve Amount.
The Company will apply 25% of the net cash proceeds from the sale of shares of its Class A Common Stock pursuant to the CSPA towards the redemption of the Series B Convertible Preferred Stock.
Await Nasdaq's confirmation of compliance with Rule 5550(b)(1) regarding stockholders' equity.
File Quarterly Report on Form 10-Q for the period ended September 30, 2025, reflecting increased stockholders' equity.

Key Dates

Date	Description
2022-06-16	Company and Midtown East Management NL, LLC entered into a Forward Purchase Agreement (FPA).
2023-03-29	Company and Partner Colorado Credit Union (PCCU) entered into a Senior Secured Promissory Note and Security Agreement for $14.5 million.
2025-04-07	Company received notice from Nasdaq regarding non-compliance with minimum stockholders' equity requirement ($2.5 million).
2025-08-27	Company issued Convertible Promissory Notes to accredited investors.
2025-09-09	Company issued additional Convertible Promissory Notes to accredited investors.
2025-09-17	Company and CREO Investments LLC entered into a Common Stock Purchase Agreement (CSPA).
2025-09-30	Effective date of Debt Cancellation Agreement with PCCU, Securities Purchase Agreement, Registration Rights Agreements, Exchange and Cancellation Agreements, Convertible Note Exchange, and CSPA Amendment. Company filed Certificate of Designation for Series B Preferred Stock.
2025-10-03	Date of signing of the 8-K report by Terrance E. Mendez.
2025-10-29	Latest practicable date for the Company to file a registration statement on Form S-1 for resale of Class A Common Stock underlying Series B Preferred Stock and Warrants.
2027-09-30	Date after which any Series B Preferred Shares remaining outstanding will trigger a 'Triggering Event'.

Recommendation

hold

The Company has taken significant steps to improve its financial position by reducing substantial debt and raising capital, which is a positive for its stability and Nasdaq listing compliance. However, the issuance of a large amount of convertible preferred stock and warrants introduces considerable potential dilution for common shareholders. The future performance is also subject to the volatile cannabis industry and regulatory changes. While the immediate financial improvements are notable, the long-term impact of dilution and the Company's ability to execute its strategy in a challenging industry warrant a cautious 'hold' recommendation until further clarity on operational performance and market integration of the new securities is available.

Keywords

SHF Holdings, SHFS, SEC Filing, 8-K, Debt Cancellation, Securities Purchase Agreement, Convertible Preferred Stock, Warrants, Nasdaq Compliance, Capital Raise, Financial Restructuring, Corporate Governance, Cannabis Industry, Risk Management, Equity Financing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.